News

The regulator, in its complete response letter (CRL), mentioned concerns regarding the manufacturing control strategy for variability of delivered dose in the TransCon PTH drug/device combination product. It

The next generation topical phosphodiesterase-4 (PDE4) inhibitor Zoryve is also indicated to treat psoriasis in the intertriginous areas. It uses a drug delivery formulation, HydroARQ Technology, which creates

The partnership, in a clinical trial, will assess the efficacy and safety of imlifidase, Hansa Biopharma’s antibody cleaving enzyme, as a pre-treatment prior to the administration of Genethon’s

Opfolda will be used as an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in LOPD (acid α glucosidase [GAA] deficiency) adult patients. The European Commission (EC)

Under the terms of the deal, Stablix will use its platform to discover new heterobifunctional small molecule drug candidates (RESTORACs) against specified targets which are involved in several

The company has invested €350m in the new research and development (R&D) centre, representing its largest single investment in the country to date. The new high-tech facility will

Known as DERMAdoctor Comfort + Joy Psoriasis Therapeutic Moisturizing Cream with 3% salicylic acid, the product will be introduced on the QVC network. The new cream will be

This partnership will focus on exploring joint venture (JV) opportunities for advancing a Phase II ready asset and the preclinical prodrug asset of BullFrog AI. The Phase II

Currently, the company has six fill finish lines in San Diego, US, that includes a new line which provides various configurations, such as vials, cartridges, and prefilled syringes.